Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2007) 14 P131


1Nuclear Medicine Department, Medical Academy, Warsaw, Poland; 2Department of Endocrinology, Medical College at Jagiellonian University, Cracow, Poland; 3Radioisotope Centre POLATOM, Otwock-Swierk, Poland.

In the 1980 s the discovery of expression of somatostatin receptors on NET cells made the use of somatostatin analogues in diagnosis and therapy possible.

The aim: Of the study was to assess response of targeted radio-nuclide therapy with radio-labelled somatostatin analogue 90Y-[DOTA0,D-Phe1,Tyr3]-octreotate (DOTATATE) in treatment of disseminated NETs.

Material and methods: 12 patients (aged 56.7+/−11.2): carcinoid-5 pts, insulinoma-1pt, gastrinoma-2 pts, pancreatic NET-2 pts, ca neauroendocrinale without primary tumor-1, stomach NET-1 pt) were enrolled in the study. Before the therapy, blood tests for hematology, kidney and liver function and CgA were performed. All patients underwent CT scans and 99mTc-HYNIC/EDDA-octreotate SRS. Treatment with 90Y-DOTATATE) was repeated every 4–6 weeks up to the total of 200 mCi/m2. Amino acids infusion was used for kidney protection.

Results: One year observation: regression of disease (PR -decrease of size and number of metastases, ↓CgA level, good clinical response) was observed in 6 pts, stable disease (SD-stable size and number of metastases, ↓CgA) in 3 pts. 3 patients died. No nephrotoxicity was observed. WBC and PLT levels were stable during therapy in 3 pts (without chemotherapy). In 1 pt with previous chemotherapy (last course a month before radiotherapy), PLT level decreased (220×103/mm3 ® 47×103/mm3after the first course); the patient died 2 months after the beginning of the therapy. In 8 pts leucopoenia was observed (< 4×103/mm3) but serious neutropenia (<2×103/mm3) was found in 3 pts with previous chemotherapy. Thrombocytopenia (PLT<100×103/mm3) was observed in 2 patients with previous chemotherapy.

Two-year observation: prolonged PR – 4 pts; SD – 3 pts, progression of disease in 2 pts: with gastrinoma and stomach NET without hormonal activity (4 and 9 months after radiotherapy). Blood tests stable.

Conclusion: PR and SD were observed in 9/12 patients with disseminated NET. Severe haematologic toxicity was mainly observed in patients after prior chemotherapy –the question of optimising the time between chemotherapy and radiotherapy is still open.

Article tools

My recent searches

No recent searches.